Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Hubbard

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Drug Metabolism and Drug Interactions|January 1, 1988
S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteersB S Chakraborty, E M Hawes, G McKay, et al.
Journal of Pharmaceutical Sciences|October 1, 1989
Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality studyB S Chakraborty, K K Midha, G McKay, et al.
Journal of Clinical Psychopharmacology|April 1, 1989
Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidolK K Midha, B S Chakraborty, D A Ganes, et al.
Journal of Pharmaceutical Sciences|March 1, 1993
Synthesis of the N-oxides of phenothiazine antipsychotic agentsT J Jaworski, M S Sardessai, M Aravagiri, et al.
Therapeutic Drug Monitoring|June 1, 1993
Clinical perspectives of some neuroleptics through development and application of their assaysK K Midha, S R Marder, T J Jaworski, et al.
Therapeutic Drug Monitoring|January 1, 1985
Therapeutic monitoring of chlorpromazine I: Pitfalls in plasma analysisJ W Hubbard, J K Cooper, E M Hawes, et al.
Schizophrenia Bulletin|January 1, 1990
Defining treatment refractoriness in schizophreniaH D Brenner, S J Dencker, M J Goldstein, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1992
Cardiorespiratory effects of the novel opioid analgesic HP 736 in the anesthetized dog and conscious goatJ W Hubbard, K W Locke, H V Forster, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Drug Metabolism and Drug Interactions|January 1, 1988
S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteersB S Chakraborty, E M Hawes, G McKay, et al.
Journal of Pharmaceutical Sciences|October 1, 1989
Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality studyB S Chakraborty, K K Midha, G McKay, et al.
Journal of Clinical Psychopharmacology|April 1, 1989
Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidolK K Midha, B S Chakraborty, D A Ganes, et al.
Journal of Pharmaceutical Sciences|March 1, 1993
Synthesis of the N-oxides of phenothiazine antipsychotic agentsT J Jaworski, M S Sardessai, M Aravagiri, et al.
Therapeutic Drug Monitoring|June 1, 1993
Clinical perspectives of some neuroleptics through development and application of their assaysK K Midha, S R Marder, T J Jaworski, et al.
Therapeutic Drug Monitoring|January 1, 1985
Therapeutic monitoring of chlorpromazine I: Pitfalls in plasma analysisJ W Hubbard, J K Cooper, E M Hawes, et al.
Schizophrenia Bulletin|January 1, 1990
Defining treatment refractoriness in schizophreniaH D Brenner, S J Dencker, M J Goldstein, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1992
Cardiorespiratory effects of the novel opioid analgesic HP 736 in the anesthetized dog and conscious goatJ W Hubbard, K W Locke, H V Forster, et al.
Pageof 12